2,4-dimethyl-5-phenyl-4,5-dihydro-oxazole | 51650-21-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,4-dimethyl-5-phenyl-4,5-dihydro-oxazole
• 英文别名: 2,4-Dimethyl-5-phenyl-Δ²-oxazolin；2,4-Dimethyl-5-phenyl-2-oxazolin；2,4-Dimethyl-5-phenyl-4,5-dihydro-1,3-oxazole
• CAS: 51650-21-6
• 化学式: C₁₁H₁₃NO
• 分子量: 175.23
• InChiKey: MMMAYBWIULJYOK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  21.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,4-dimethyl-5-phenyl-4,5-dihydro-oxazole 在 间氯过氧苯甲酸 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以93%的产率得到
  参考文献：
  名称：

  四氟硼酸叔胺和亚胺的作用

  摘要：

  衍生自二氢异喹啉的恶唑烷鎓盐1是向伯胺的氧转移试剂，伯胺可导致亚硝基衍生物（如果R =烷基）或硝基化合物（如果R =芳基），叔胺导致N-氧化物，仲胺和亚胺导致到相应的硝酮。

  DOI：

  10.1016/s0040-4020(01)89569-7
• 作为产物：
  描述：

  (+/-)-N-acetylnorephedrine 在 PPA 作用下， 反应 3.0h， 生成 2,4-dimethyl-5-phenyl-4,5-dihydro-oxazole
  参考文献：
  名称：

  Ardabilchi,N. et al., Journal of the Chemical Society. Perkin transactions I, 1979, p. 539 - 543

  摘要：

  DOI：

文献信息

• PYRAZOLE COMPOUNDS HAVING THERAPEUTIC EFFECT ON MULTIPLE MYELOMA
  申请人：Nishino Taito

  公开号：US20130253204A1

  公开（公告）日：2013-09-26

  Novel therapeutic agents for myeloma are provided. A therapeutic agent for multiple myeloma containing a pyrazole compound represented by the formula (1): wherein R 1 is C 1 -C 6 alkyl, C 1 -C 6 alkyl substituted with R 17 , C 1 -C 6 haloalkyl, phenyl, phenyl substituted with a R 11 's or the like, R 2 is a hydrogen atom, C 1 -C 6 alkyl, phenyl or phenyl optionally substituted with e R 21 's or the like, R 3 is a hydrogen atom or the like, X is a single bond or —(CR 6 , R 7 ) n —, each of R 4 and R 5 is independently C 1 -C 6 alkyl or the like, R 6 and R 7 are hydrogen atoms or C 1 -C 6 alkyl, R 8 is phenyl, phenyl optionally substituted with k R 81 's or the like, a tautomer of the compound or a pharmaceutically acceptable salt or solvate thereof, as an active ingredient.

  提供了用于骨髓瘤的新型治疗药物。一种用于多发性骨髓瘤的治疗剂，包含由式（1）表示的吡唑烷化合物：其中R1是C1-C6烷基，C1-C6烷基取代为R17，C1-C6卤代烷基，苯基，苯基取代为R11或类似物，R2是氢原子，C1-C6烷基，苯基或可选地取代为e个R21或类似物，R3是氢原子或类似物，X是单键或—（CR6，R7)n—，R4和R5分别独立地是C1-C6烷基或类似物，R6和R7是氢原子或C1-C6烷基，R8是苯基，苯基可选地取代为k个R81或类似物，所述化合物的互变异构体或其药用上可接受的盐或溶剂，作为活性成分。
• METHOD FOR PRODUCING AROMATIC COMPOUND
  申请人：Sumitomo Chemical Company, Limited

  公开号：US20150322101A1

  公开（公告）日：2015-11-12

  A method is provided for producing an aromatic compound, including a step of mixing a compound represented by formula (A) and a compound represented by formula (B): in the presence of at least one phosphine compound selected from the group consisting of a phosphine represented by formula (C) and a phosphonium salt represented by formula (F): a base, a palladium compound, and an aprotic organic solvent.

  提供一种生产芳香化合物的方法，包括以下步骤：在至少一种磷化物化合物的存在下，将由化学式(A)表示的化合物与由化学式(B)表示的化合物混合；所述磷化物化合物选择自由化学式(C)表示的磷化物和由化学式(F)表示的磷酸盐；还包括碱、钯化合物和无水有机溶剂。
• METHOD FOR PRODUCING HEMATOPOIETIC STEM CELLS USING PYRAZOLE COMPOUNDS
  申请人：Asai Ayako

  公开号：US20140057353A1

  公开（公告）日：2014-02-27

  An expanding agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful as a therapy for various hematopoietic diseases and useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy is provided. A method of producing hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises expanding hematopoietic stem cells by culturing hematopoietic stem cells ex vivo in the presence of a compound represented by the formula following (I), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof (wherein R 1 to R 8 are as defined in the description).

  提供一种用于治疗各种造血系统疾病的造血干细胞和/或造血祖细胞扩增剂，并可用于提高基因治疗中基因转移效率的方法。一种生产造血干细胞和/或造血祖细胞的方法，包括在化合物公式（I）所表示的化合物、其互变异构体或药学上可接受的盐或其溶剂的存在下，在体外培养造血干细胞以扩增造血干细胞。其中R1至R8的定义如说明书中所示。
• METHOD FOR PRODUCING HEMATOPOIETIC STEM CELLS USING PYRAZOLE COMPOUND
  申请人：Nissan Chemical Industries, Ltd.

  公开号：EP2647697A1

  公开（公告）日：2013-10-09

  An expanding agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful as a therapy for various hematopoietic diseases and useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy is provided. A method of producing hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises expanding hematopoietic stem cells by culturing hematopoietic stem cells ex vivo in the presence of a compound represented by the formula following (I), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof (wherein R1 to R8 are as defined in the description).

  提供了一种造血干细胞和/或造血祖细胞扩增剂，可用于治疗各种造血疾病，并可提高基因治疗中基因转移到造血干细胞的效率。 一种生产造血干细胞和/或造血祖细胞的方法，它包括在存在下式(I)所代表的化合物、该化合物的同系物或药学上可接受的盐或其溶液（其中R1至R8如描述中所定义）的情况下，通过体外培养造血干细胞来扩增造血干细胞。
• Butt, Mohammed I.; Neilson, Douglas G.; Watson, Kathleen M., Journal of the Chemical Society. Perkin transactions I, 1977, # 20, p. 2328 - 2332
  作者：Butt, Mohammed I.、Neilson, Douglas G.、Watson, Kathleen M.、Zakir-Ullah

  DOI：——

  日期：——